LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, May 30, 2019 /PRNewswire/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a
biopharmaceutical company focused on developing novel therapeutics
to treat unmet needs in patients with liver, respiratory and kidney
disease, today announced that members of the management team will
provide a business overview and update at the 2019 Jeffries Global
Healthcare Conference at 14:30 EDT on Thursday, June 6, 2019 and at the Raymond James
Life Sciences & MedTech Conference at 15:35 EDT on Wednesday, June 19, both in
New York, NY.
The presentations will be webcast live on the Webcasts
page of the Investors & Media section of Prometic's
website, or by following the links below in your web browser. An
archived replay of each webcast will be available on Prometic's
website for at least 7 days after each live event concludes.
- Jeffries: http://wsw.com/webcast/jeff118/pli/
- Raymond
James: http://wsw.com/webcast/rj115/pli/
About Prometic
Prometic (www.prometic.com) is an innovative biopharmaceutical
corporation with a broad pipeline of small molecule therapeutics
under development to treat unmet needs in patients with liver,
respiratory and kidney disease, including rare diseases. Prometic's
differentiated research involves the study of two
G-protein-coupled-receptors, GPR40 and GPR84. These drug candidates
have a dual mode-of-action as agonists ("stimulators") of GPR40 and
antagonists ("inhibitors") of GPR84. Our lead drug candidate,
PBI-4050, is expected to enter Phase 3 clinical studies for the
treatment of Alström Syndrome in 2019. A second drug candidate,
PBI-4547, is expected to enter Phase 1 clinical studies in 2019.
Prometic also has leveraged its experience in bioseparation
technologies to isolate and purify biopharmaceuticals from human
plasma. The lead plasma-derived therapeutic product is Ryplazim™
(plasminogen) which the Company expects to file a BLA with the US
FDA in 2019 seeking approval to treat patients with congenital
plasminogen deficiency. The Corporation also operates a contract
development and manufacturing operation in the United Kingdom, deriving revenue through sales
of affinity chromatography media. Prometic has active business
operations in Canada, the United States and the United Kingdom. For more information, please
visit www.prometic.com.
Forward Looking Statements
This press release contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
Prometic's Annual Information Form for the year ended December 31, 2018, under the heading "Risk and
Uncertainties related to Prometic's business". As a result, we
cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations.
View original
content:http://www.prnewswire.com/news-releases/prometic-life-sciences-to-present-at-two-upcoming-june-investor-conferences-300859132.html
SOURCE ProMetic Life Sciences Inc.